Plain-English translation of NCT07691047 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is studying how to better predict and manage side effects in patients with chronic lymphocytic leukemia who are being treated with venetoclax, a targeted cancer medication. Researchers want to reassess the risk of a specific type of side effect (called hemolytic syndrome) before patients start the medication, when combined with other approved treatments. This could help simplify how doctors prepare patients for treatment and prevent serious complications.
When this medication was first used alone, it could cause a dangerous condition where cancer cells break down too quickly, leading to harmful substances flooding the bloodstream. Doctors now use the medication with partner drugs, which appears to reduce this risk. This trial wants to confirm whether reassessing risk at this new stage of treatment could make the process safer and easier for patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would have your risk for side effects reassessed just before starting the medication, likely including imaging scans and blood tests to measure your lymph node size and cell counts. You would then receive the medication combined with one of the approved partner treatments according to your doctor's plan. The study involves monitoring your safety and response to treatment over time, with regular follow-up visits to check how you are doing.
AI-generated summary from trial data · Oct 22, 2026 · Not medical advice
France